Lenalidomide (Revlimid) for low- and intermediate-1-risk myelodysplastic syndromes with deletion 5q chromosomal abnormality - horizon scanning review
NHSC
Record ID 32005001219
English
Authors' objectives:
This study aims to assess the effectiveness of Lenalidomide (Revlimid) for low- and intermediate-1-risk myelodysplastic syndromes with deletion 5q chromosomal abnormality.
Authors' recommendations:
Lenalidomide (Revlimid, CC-5013), an oral immunomodulatory thalidomide analogue, is in phase III trials for patients with low- and intermediate-1-risk myelodysplastic syndromes (MDS) with deletion 5q chromosomal abnormality alone or in combination with other cytogenetic abnormalities. Lenalidomide does not have the teratogenic effects of thalidomide. Two uncontrolled phase II trials (n=146&214) in red blood cell (RBC) transfusion-dependent patients published in abstract demonstrate the erythropoietic activity of lenalidomide in lower risk MDS and indicate that lenalidomide has significant haematologic and cytogenetic remitting activity in patients with deletion 5q chromosomal abnormality.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Angiogenesis Inhibitors
- Thalidomide
- Myelodysplastic Syndromes
- Lenalidomide
- Immunologic Factors
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.